Skip to content
Gold markets broke down rather drastically on Thursday, and Friday started to see more selling. At this point, we are testing the bottom of a huge flag, which is starting to get a bit extended....
Every investor in Iterum Therapeutics plc (NASDAQ:ITRM) should be aware of the most powerful shareholder groups......
CVS Health (NYSE:CVS) stock got a lift on Nov. 6 after delivering an earnings report that beat on both the top and bottom lines. The company also gave improved earnings estimates for the rest of 2019.Source: Shutterstock Earnings of $1.85 per share exceeded the consensus estimate of $1.77 per share. CVS also reported $64.8 billion in revenue which was above expectations of $62.99 billion. For the full year CVS gave an earnings per share (EPS) range between $6.97 and $7.05. This was an increase from their prior estimate of between $6.89 and $7.In a statement submitted with the earnings report, CEO Larry Merlo said, "Our third quarter results build on the positive momentum we have seen across the company since the beginning of the year. All of our core businesses performed in line with or above expectations, reflecting strong operational execution."InvestorPlace - Stock Market News, Stock Advice & Trading Tips *...
The U.S. Food and Drug Administration said on Friday it had approved a treatment for a rare blood disorder from Celgene Corp, which is in the process of being bought by Bristol-Myers Squibb Co. Reblozyl, which has been jointly developed by Celgene and Acceleron Pharma Inc, is meant for treatment of anemia in patients with beta thalassemia, who require regular red blood cell transfusions. Beta thalassemia is an inherited disorder that reduces the production of hemoglobin in blood, which can lead to lack of oxygen in many parts of the body and anemia, the FDA said....
Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said. The drug was jointly developed by Acceleron and Celgene, which is being bought by Bristol-Myers Squibb Co. A 75 mg vial of Reblozyl will be available at a wholesale acquisition cost of $10,323.53 per vial, Acceleron said....
Whilst it may not be a huge deal, we thought it was good to see that the U.S. Silica Holdings, Inc. (NYSE:SLCA......
Q3 2019 StoneMor Partners LP Earnings Call...
